ProCE Banner Activity

Challenging the Current Treatment Paradigm for Patients With Follicular Lymphoma: Recent and Emerging Evidence

Tool

Use this Interactive Decision Support Tool to compare your approach for treating patients with follicular lymphoma with the strategies recommended by 5 expert hematologists.

Released: March 31, 2023

Begin Activity

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Jean Louise Koff

Jean Louise Koff, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Pallawi Torka

Pallawi Torka, MD

Assistant Professor of Oncology
Lymphoma Division
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD: consultant: Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol-Myers Squibb, Epizyme, Kura, Kymera, Morphosys, Novartis, Nurix, Roche/Genentech, SeaGen, TG Therapeutics, Verastem, X4 Pharmaceuticals; speaker: BeiGene, SeaGen; researcher: Morphosys.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys AG, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; researcher (paid to institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Jean Louise Koff, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jean L. Koff, MD, MSc: consultant: BeiGene, Janssen/Pharmacyclics, Gamida Cell, MorphoSys, TG Therapeutics; researcher: Atara, Celgene, Janssen/Pharmacyclics, Oncternal, Viracta.

Pallawi Torka, MD

Assistant Professor of Oncology
Lymphoma Division
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Pallawi Torka, MD: consultant/advisor/speaker: ADC Therapeutics, Genentech, Lilly, Seagen, TG Therapeutics.